The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant

Virology

Volumn 427, Issue 1, 2012, Pages 25-33

  Provine, Nicholas M ^a,c   Cortez, Valerie ^a,b   Chohan, Vrasha ^a   Overbaugh, Julie ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Human immunodeficiency virus; Neutralizing antibodies; Producer cell; Pseudovirus

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY VRC01; UNCLASSIFIED DRUG;

ARTICLE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; LYMPHOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; KENYA; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84858075219     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.02.001     Document Type: Article

References (40)

1. Blay W., Kasprzyk T., Misher L., Richardson B., Haigwood N. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J. Virol. 2007, 81:13037-13049.
2. Blish C., Blay W., Haigwood N., Overbaugh J. Transmission of HIV-1 in the face of neutralizing antibodies. Curr. HIV Res. 2007, 5:578-587.
3. Blish C.A., Nedellec R., Mandaliya K., Mosier D.E., Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007, 21:693-702.
4. Blish C.A., Nguyen M.-A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 2008, 5:91-103.
5. Blish C.A., Jalalian-Lechak Z., Rainwater S., Nguyen M.-A., Dogan O.C., Overbaugh J. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J. Virol. 2009, 83:7783-7788.
6. Brown B., Wieczorek L., Sanders-Buell E., Rosa Borges A., Robb M., Birx D., Michael N., McCutchan F., Polonis V. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008, 375:529-538.
7. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
8. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
9. Chung A., Rollman E., Johansson S., Kent S.J., Stratov I. The utility of ADCC responses in HIV infection. Curr. HIV Res. 2008, 6:515-519.
10. Doria-Rose N., Learn G., Rodrigo A., Nickle D., Li F., Mahalanabis M., Hensel M., McLaughlin S., Edmonson P., Montefiori D., Barnett S., Haigwood N., Mullins J. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 2005, 79:11214-11224.
11. Duenas-Decamp M.J., Peters P., Burton D., Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 2008, 82:5807-5814.
12. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 2009, 4:388-393.
13. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36:59-74.
14. Lavreys L., Baeten J.M., Kreiss J.K., Richardson B.A., Chohan B.H., Hassan W., Panteleeff D.D., Mandaliya K., Ndinya-Achola J.O., Overbaugh J. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J. Infect. Dis. 2004, 189:303-311.
15. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
16. Long E.M., Rainwater S.M.J., Lavreys L., Mandaliya K., Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 2002, 18:567-576.
17. Louder M.K., Sambor A., Chertova E., Hunte T., Barrett S., Ojong F., Sanders-Buell E., Zolla-Pazner S., McCutchan F.E., Roser J.D., Gabuzda D., Lifson J.D., Mascola J.R. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005, 339:226-238.
18. Lovelace E., Xu H., Blish C.A., Strong R., Overbaugh J. The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. Virology 2011, 421:235-244.
19. Mann A.M., Rusert P., Berlinger L., Kuster H., Günthard H.F., Trkola A. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 2009, 23:1659-1667.
20. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
21. Mascola J.R., Louder M.K., Winter C., Prabhakara R., De Rosa S.C., Douek D.C., Hill B.J., Gabuzda D., Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 2002, 76:4810-4821.
22. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
23. Neilson J.R., John G.C., Carr J.K., Lewis P., Kreiss J.K., Jackson S., Nduati R.W., Mbori-Ngacha D., Panteleeff D.D., Bodrug S., Giachetti C., Bott M.A., Richardson B.A., Bwayo J., Ndinya-Achola J., Overbaugh J. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J. Virol. 1999, 73:4393-4403.
24. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
25. Poss M., Overbaugh J. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J. Virol. 1999, 73:5255-5264.
26. Provine N.M., Puryear W.B., Wu X., Overbaugh J., Haigwood N.L. The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity. J. Virol. 2009, 83:9002-9007.
27. Rainwater S.M.J., Wu X., Nduati R., Nedellec R., Mosier D., John-Stewart G., Mbori-Ngacha D., Overbaugh J. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr. HIV Res. 2007, 5:189-197.
28. Raska M., Takahashi K., Czernekova L., Zachova K., Hall S., Moldoveanu Z., Elliott M.C., Wilson L., Brown R., Jancova D., Barnes S., Vrbkova J., Tomana M., Smith P.D., Mestecky J., Renfrow M.B., Novak J. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J. Biol. Chem. 2010, 285:20860-20869.
29. Sawyer L.S., Wrin M.T., Crawford-Miksza L., Potts B., Wu Y., Weber P.A., Alfonso R.D., Hanson C.V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 1994, 68:1342-1349.
30. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84:1439-1452.
31. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70:1100-1108.
32. Utachee P., Nakamura S., Isarangkura-Na-Ayuthaya P., Tokunaga K., Sawanpanyalert P., Ikuta K., Auwanit W., Kameoka M. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J. Virol. 2010, 84:4311-4320.
33. Vodicka M.A., Goh W.C., Wu L.I., Rogel M.E., Bartz S.R., Schweickart V.L., Raport C.J., Emerman M. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997, 233:193-198.
34. Walker L.M., Phogat S.K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Investigators P.G.P., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
35. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
36. Willey R., Shibata R., Freed E., Cho M., Martin M. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J. Virol. 1996, 70:6431-6436.
37. Wu X., Parast A.B., Richardson B.A., Nduati R., John-Stewart G., Mbori-Ngacha D., Rainwater S.M.J., Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 2006, 80:835-844.
38. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
39. Zhang Y.J., Fredriksson R., McKeating J.A., Fenyö E.M. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 1997, 238:254-264.
40. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Tewari K., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.